Lundbeckfonden Ventures

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 59
Average round size
info
The average size of a deal this fund participated in
$31M
Portfolio companies 33
Rounds per year 4.54
Lead investments 11
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.44
Exits 17
Key employees 3
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Pharmaceutical
  • Medical
Summary

In 2009 was created Lundbeckfonden Ventures, which is appeared as VC. The main office of represented VC is situated in the Copenhagen. The company was established in Europe in Denmark.

Besides them, we counted 3 critical employees of this fund in our database.

The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Lundbeckfonden Ventures, startups are often financed by New Enterprise Associates, SR One, TPG Biotech. The meaningful sponsors for the fund in investment in the same round are Pfizer Venture Investments, Seventure Partners, OUP (Osage University Partners). In the next rounds fund is usually obtained by OUP (Osage University Partners), New Enterprise Associates, SR One.

Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. For fund there is no match between the location of its establishment and the land of its numerous investments - United States. The fund has specific favorite in a number of founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little. Among the various public portfolio startups of the fund, we may underline DBV Technologies, SNIPR Biome, Cydan Among the most successful fund investment fields, there are Biotechnology, Therapeutics.

The higher amount of exits for fund were in 2017. The fund is constantly included in 2-6 investment rounds annually. The important activity for fund was in 2016. Despite it in 2019 the fund had an activity. Speaking about the real fund results, this VC is 16 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this Lundbeckfonden Ventures performs on 1 percentage points less the average number of lead investments. The common things for fund are deals in the range of 10 - 50 millions dollars.

Read more

Funds with similar focus

Funds from Denmark
Funds with similar focus located in Denmark:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

LEXEO Therapeutics

Biotechnology
Life Science
Therapeutics
$100M09 Sep 2021 New York, New York, United States

Aura Biosciences

Biotechnology
Health Care
Pharmaceutical
$80M22 Mar 2021 Cambridge, Massachusetts, United States

LEXEO Therapeutics

Biotechnology
Life Science
Therapeutics
$85M07 Jan 2021 New York, United States

Reneo Pharmaceuticals

Biotechnology
Medical
Pharmaceutical
$95M09 Dec 2020 San Diego, California, United States

VarmX

Manufacturing
Pharmaceutical
Therapeutics
$37M08 Jul 2020 Leiden, South Holland, Netherlands

Amplyx Pharmaceuticals

Biotechnology
Clinical Trials
Medical
Pharmaceutical
$53M19 May 2020 San Diego, California, United States

IO Biotech

Biotechnology
Health Care
Therapeutics
$9M12 May 2020 Copenhagen, Capital Region of Denmark, Denmark

SANIFIT

Biotechnology
Hospital
Medical
$65M26 Jun 2019 Palma De Mallorca, Islas Baleares, Spain

Reneo Pharmaceuticals

Biotechnology
Medical
Pharmaceutical
$50M20 May 2019 San Diego, California, United States
News
Aura Biosciences Announces Oversubscribed $80 Million Financing

– Aura Biosciences closed an oversubscribed $80m financing.
– The financing was led by Matrix Capital Management and Surveyor Capital (a Citadel company) with participation from new investors, including Rock Springs Capital, Adage Capital Management LP and Velosity Capital.
– Existing investors Medicxi, Advent Life Sciences, Lundbeckfonden Ventures, Arix Bioscience, Chiesi Ventures, Ysios Capital and Columbus Venture Partners also participated in the round.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Lundbeckfonden Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: